炎症性肠病（IBD）和代谢综合征（MS）的发病率近几十年不断升高，两者有相似的临床特征，如心血管疾病风险增加、非酒精性肝硬化发病率增加和肥胖等。MS是IBD的常见共病，可显著增加CD患者的住院率，且与患者预后不良有关。两者病理生理学机制相似，包括免疫失衡和慢性炎症、脂肪组织功能失调、肠道菌群紊乱。本文就IBD与MS关系的研究进展做一综述，以期从MS中探寻IBD新的药物治疗方法以及为消化科医生重视和早期识别MS患者和相关高危因素，更加科学地管理IBD患者提供参考。“,”The incidence of inflammatory bowel disease (IBD) and metabolic syndrome (MS) has been increasing in recent decades. There are some common clinical features between the two diseases, including increased risk of cardiovascular disease, increased incidence of non-alcoholic fatty liver disease and obesity. MS is a common comorbidities of IBD, and it can significantly increase the hospitalization rate of patients with CD, and may be associated with poor prognosis of CD patients. Latest studies have found some similarities in pathophysiological mechanisms between the two diseases as well, such as immune imbalance and chronic inflammation, adipose tissue dysfunction, and intestinal flora disorder. This article summarizes the research progress of the relationship between IBD and MS, in order to explore new drug treatment methods for IBD from MS and provide reference for gastroenterologists to pay attention to the early identification of MS patients and the related high-risk factors, and to manage IBD patients more scientifically.